VTVT (vTv Therapeutics) Common Stock : $0.03 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is vTv Therapeutics Common Stock?

vTv Therapeutics's quarterly common stock increased from Jun. 2024 ($0.03 Mil) to Sep. 2024 ($0.03 Mil) but then stayed the same from Sep. 2024 ($0.03 Mil) to Dec. 2024 ($0.03 Mil).

vTv Therapeutics's annual common stock stayed the same from Dec. 2022 ($0.03 Mil) to Dec. 2023 ($0.03 Mil) but then increased from Dec. 2023 ($0.03 Mil) to Dec. 2024 ($0.03 Mil).

vTv Therapeutics Common Stock Historical Data

The historical data trend for vTv Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

vTv Therapeutics Common Stock Chart

vTv Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

0.77

0.90

0.03

vTv Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.03

vTv Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

vTv Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » vTv Therapeutics Inc (NAS:VTVT) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

5VT0:Germany

Address

3980 Premier Drive, Suite 310, High Point, NC, USA, 27265

Website

https://www.vtvtherapeutics.com

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

Executives

Paul J Sekhri	director, officer: President and CEO	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Steven L. Tuch	officer: Chief Financial Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
John A Fry	director	C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103
Jonathan Isaacsohn	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Fahed Al-marzooqi	director	AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000
Keith R. Harris	director	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Hersh Kozlov	director	WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003
Howard L. Weiner	director	4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265
Chandresh Harjivan	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Al-nahyan Tahnoon Bin Zayed S.	10 percent owner	OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000
G42 Investments Ai Holdings Rsc Ltd.	director, 10 percent owner	OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000
Barry K. Brown	officer: Chief Accounting Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Rich S. Nelson	director, officer: Acting Chief Executive Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Ronald O Perelman	10 percent owner	35 EAST 62ND STREET, NEW YORK NY 10021
Deepa Prasad	director, officer: President and CEO	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265